[Randomly clinical study of ITP and NP regimens in the treatment of non-small cell lung cancer].
作者信息
Yan Xi, Hou Mei, Gou Hongfeng
机构信息
Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R.China.
出版信息
Zhongguo Fei Ai Za Zhi. 2004 Feb 20;7(1):64-6. doi: 10.3779/j.issn.1009-3419.2004.01.16.
BACKGROUND
To evaluate the efficacy and toxicity of ITP (ifosfamide + perarubicin + cisplatin) and NP (vinorelbine + cisplatin) regimens in the treatment of advanced non small cell lung cancer (NSCLC).
METHODS
One hundred inoperatable or recurrent patients with stage III and IV NSCLC were randomized into ITP group and NP group treated by the two regimens responsively for 2 or 3 cycles.
RESULTS
The overall response rate was 51.5% for ITP group and 50.9% for the NP group, respectively. There was no statistically significant difference of the overall response rate between the two groups ( P > 0.05). The major side effects were leukopenia and gastrointestinal reaction. The leukopenia incidence was higher in ITP group than that in NC group ( P < 0.05).
CONCLUSIONS
Both ITP and NP regimens are effective for the advanced NSCLC. Compared with ITP regimen, NP regimen has less bone marrow toxicity than ITP regimen.
Zotero 插件